From: Galectin-3 predicts response and outcomes after cardiac resynchronization therapy
Univariate OR [CI 95%] | p* | Multivariable OR [CI 95%] | p* | |
---|---|---|---|---|
Age ≥ 65 year-old | 0.42 [0.09–1.99] | 0.29 | ||
CAD | 0.41 [0.11–1.50] | 0.18 | ||
Female sex | 1.20 [0.28–5.10] | 0.80 | ||
Minnesota ≥ 46 | 0.42 [0.10–1.82] | 0.26 | ||
Gal-3 ≥ 22 (ng/mL) | 0.27 [0.07–1.08] | 0.07 | 0.11 [0.02–0.40] | < 0.001 |
LVEF ≥ 25% | 1.03 [0.24–4.43] | 0.97 | ||
LVESV (mL/m2) | 0.59 [0.97–1.02] | 0.65 | ||
Presence of LGE | 0.18 [0.04–0.74] | 0.01 | ||
LGE ≥ 14% | 0.13 [0.03–0.57] | 0.003 | 0.17 [0.03–0.62] | 0.007 |
QRS < 150 ms | 1.83 [0.20–16.51] | 0.57 | ||
Selvester ≥ 24% | 0.65 [0.17–2.54] | 0.54 | ||
Creatinine clearance (mL/min/1.73 m2) | 0.99 [0.96–1.02] | 0.40 | ||
Diabetes | 0.29 [0.08–1.05] | 0.06 | 0.16 [0.04–0.64] | 0.008 |